Applied Sciences· 2026Q2· Review
Modulation of the Endocannabinoid System by Cannabis sativa Bioactives in Alzheimer’s Disease: Therapeutic and Nutritional Implications
- 0citations
- Q2SCImago
- 2026year
Short summary
Cannabis sativa bioactives, including CBD and THC, show potential for modulating neuroinflammation, oxidative stress, and amyloid-β aggregation in Alzheimer's disease (AD), with hemp-derived products offering complementary nutritional benefits.
AI-generated from the title and abstract; the full text is not read.
Key points
- Cannabinoids like CBD and THC may target neuroinflammation, oxidative stress, amyloid-β, and tau pathology in Alzheimer's disease.
- Non-cannabinoid compounds from Cannabis sativa, including polyphenols and flavonoids, also exhibit neuroprotective properties.
- Hemp seeds and derived products offer nutritional bioactives that could complement therapeutic approaches.
- Current clinical evidence primarily supports cannabinoid use for behavioral and neuropsychiatric symptom improvement in AD.
AI-generated from the title and abstract; the full text is not read.
Abstract
Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, neuroinflammation, oxidative stress, amyloid-β accumulation, and tau pathology. Current therapies provide limited symptomatic relief, highlighting the need for novel therapeutic and nutritional approaches. Objective: This review aimed to evaluate the therapeutic and nutritional implications of Cannabis sativa and its bioactive compounds in AD management, with emphasis on molecular mechanisms, clinical evidence, extraction technologies, and emerging therapeutic opportunities. Methods: A comprehensive review of the scientific literature was conducted, focusing on cannabinoids, non-cannabinoid phytochemicals, hemp-derived nutritional compounds, preclinical findings, clinical studies, and recent advances related to AD. Results: Evidence indicates that cannabinoids, particularly cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), may modulate neuroinflammation, oxidative stress, amyloid-β aggregation, tau hyperphosphorylation, and neuronal survival pathways. Emerging compounds, including acidic cannabinoids, minor cannabinoids, polyphenols, flavonoids, hemp-derived bioactive peptides, and root alkaloids, have demonstrated additional neuroprotective potential. Clinical studies primarily support cannabinoid-based interventions for improving behavioral and neuropsychiatric symptoms rather than modifying disease progression. Hemp seeds and hemp-derived products also provide nutritional bioactives with potential complementary benefits. Conclusion: Cannabis sativa represents a promising source of therapeutic and nutritional bioactive compounds for AD management. However, larger standardized clinical trials are required to confirm efficacy, safety, and disease-modifying potential before widespread clinical application can be recommended.
The authors' abstract, as published at the source. Applied Sciences, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pharmacology (Medicine)
PharmacologyMedicine